Archimedes
Janelle Burkle is an accomplished professional with extensive experience in client services and management across various organizations. Currently serving as Vice President of Specialty Services at Archimedes, Janelle oversees account management, product management, and customer service. Previous roles include Director of Pharmacy Client Services at Drexi, Vice President of Client Services at MedOne Pharmacy Benefit Solutions—with notable achievements in client retention and business growth—Consultant Level Project Manager at Willis Towers Watson, and Account Manager at Magellan Health. Janelle's foundational experience spans from implementation management at CVS Caremark Corporation to senior account management at CDS Global, demonstrating a strong capability in leading teams, managing complex projects, and driving client satisfaction. Janelle holds an MBA in Business Administration from the University of Dubuque and various other degrees in business and finance.
Archimedes
Specialty drug spend is the single fastest growing healthcare expense. Recognizing the potential clinical value of these drugs, plan sponsors want to provide them to their enrollees—but to maintain an affordable, sustainable benefit in this rapidly changing environment, they must also control costs. To do this, plan sponsors need quantitative information about which strategies work to target drugs to those in need of them and they must minimize use of clinically ineffective therapies and reduce waste. However, the guidance and services provided to plan sponsors to achieve these goals is not always objective or complete. Recognizing these challenges, Archimedes offers specialty drug management solutions for health plans, TPAs, employers, labor groups, and other plan sponsors across the U.S, without any potential conflicted financial relationships with specialty pharmacies or PBMs. Like the scientist and inventor who provided the inspiration for our name, we leverage an unmatched combination of analytic expertise, technological capabilities, experience, and pragmatism to provide plan sponsors with the support that they really need to control the growing cost of specialty drugs across the pharmacy and medical benefits. Fundamental to our business is the belief that full visibility into the economics and clinical performance of a specialty drug program is critical to making informed decisions concerning specialty drug management.